Term
Treatment for central DI?
Nephrogenic DI? |
|
Definition
Central: dDAVP (desmopressin, ADH analog)
Nephrogenic: HCTZ, indomethacin, amiloride |
|
|
Term
|
Definition
| Demeocycline, H2O restriction |
|
|
Term
|
Definition
Rapid acting insulin
Type 1DM, Type 2DM, gestational DM, hyperkalemia, stress-induced hyperglycemia
Hypoglycemia, hypersensitivity (rare), orthostatic hyptotension (rare) |
|
|
Term
|
Definition
Rapid acting insulin
Type 1DM, Type 2DM, gestational DM, hyperkalemia, stress-induced hyperglycemia
Hypoglycemia, hypersensitivity (rare), orthostatic hyptotension (rare) |
|
|
Term
|
Definition
Intermediate acting insulin
Type 1DM, Type 2DM, gestational DM, hyperkalemia, stress-induced hyperglycemia
Hypoglycemia, hypersensitivity (rare), orthostatic hyptotension (rare) |
|
|
Term
|
Definition
Long acting insulin
Type 1DM, Type 2DM, gestational DM, hyperkalemia, stress-induced hyperglycemia
Hypoglycemia, hypersensitivity (rare), orthostatic hyptotension (rare) |
|
|
Term
|
Definition
Long acting insulin
Type 1DM, Type 2DM, gestational DM, hyperkalemia, stress-induced hyperglycemia
Hypoglycemia, hypersensitivity (rare), orthostatic hyptotension (rare) |
|
|
Term
|
Definition
1st generation sulfonylurea; close K channel in beta-cell membrane, triggers insulin release
Type 2 DM only.
Disulfiram-like effects |
|
|
Term
|
Definition
1st generation sulfonylurea; close K channel in beta-cell membrane, triggers insulin release
Type 2 DM only.
Disulfiram-like effects |
|
|
Term
|
Definition
2nd generation sulfonylurea; close K channel in beta-cell membrane, triggers insulin release
Type 2 DM only.
Hypoglycemia, rare agranulocytosis |
|
|
Term
|
Definition
2nd generation sulfonylurea; close K channel in beta-cell membrane, triggers insulin release
Type 2 DM only.
Hypoglycemia, rare agranulocytosis |
|
|
Term
|
Definition
2nd generation sulfonylurea; close K channel in beta-cell membrane, triggers insulin release
Type 2 DM only.
Hypoglycemia, rare agranulocytosis |
|
|
Term
|
Definition
A biguanide; decreases gluconeogenesis (main action), also increases glycolysis, increases peripheral insulin sensitivity. Mechanism unknown.
Type 2DM, less often in type 1DM.
Lactic acidosis (CI in renal failure). |
|
|
Term
|
Definition
A thiazolidinedione. Increases insulin sensitivity in peripheral tissue by binding to PPAR-gamma nuclear TF. Increase adiponectin levels, fatty acid transport protein, insulin receptor, GLUT4.
Monotherapy for DM2, or with other agents.
Weight gain, edema. Hepatotoxic. CV toxic. |
|
|
Term
|
Definition
A thiazolidinedione. Increases insulin sensitivity in peripheral tissue by binding to PPAR-gamma nuclear TF. Increase adiponectin levels, fatty acid transport protein, insulin receptor, GLUT4.
Monotherapy for DM2, or with other agents.
Weight gain, edema. Hepatotoxic. CV toxic. |
|
|
Term
|
Definition
alpha-glucosidase inhibitor. Delays sugar hydrolysis/absorption at brush border, lowers post-prandial hyperglycemia.
Monotherapy in DM2, or combo with other agents.
Osmotic diarrhea, flatulence. |
|
|
Term
|
Definition
alpha-glucosidase inhibitor. Delays sugar hydrolysis/absorption at brush border, lowers post-prandial hyperglycemia.
Monotherapy in DM2, or combo with other agents.
Osmotic diarrhea, flatulence. |
|
|
Term
|
Definition
Amylin analog (usually released with insulin). Slows gastric emptying, promotes satiety, inhibits glucagon secretion.
DM1 and insulin-using DM2.
Hypoglycemia, nausea, diarrhea. |
|
|
Term
|
Definition
GLP-1 analog. Mechanism unknown. Enhances insulin secretion, suppresses glucagon secretion, slows gastric emptying.
DM type 2, adjunct to other oral meds.
Nausea, vomiting, pancreatitis. |
|
|
Term
Propylthiouracil
Mech
Use
Tox |
|
Definition
Inhibit thyroperoxidase; prevent organification of iodide and DIT/MIT coupling. Also inhibit peripheral conversion of T4 to T3.
Hyperthyroidism.
Skin rash, agranulocytosis, aplastic anemia. |
|
|
Term
|
Definition
Inhibit thyroperoxidase; prevent organification of iodide and DIT/MIT coupling.
Hyperthyroidism.
Skin rash, agranulocytosis, aplastic anemia, teratogen. |
|
|
Term
|
Definition
Thyroxine replacement
Hypothyroidism, myxedema
Tachycardia, heat intolerance, tremors, arrythmias |
|
|
Term
Triiodothyonine
Mech
Use
Tox |
|
Definition
Thyroxine replacement
Hypothyroidism, myxedema
Tachycardia, heat intolerance, tremors, arrythmias |
|
|
Term
|
Definition
| Adrenocorticolytic; used for adrenocortical carcinoma. |
|
|
Term
|
Definition
Inhibits 11-beta-hydroxylase, preventing cortisol synthesis.
Used to test HPA axis - if intact, should see rise in urine 11-deoxycortisol metabolites (17-hydroxy-corticosteroids). |
|
|
